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ABSTRACT
Despite a substantial body of research in direct-to-consumer advertising (DTCA) for
prescription drugs, what is missing from much of the existing discussion on DTCA
disclosure is a focus on the roles of consumers’ individual motivation and ability factors
in processing risk disclosures. Guided by the Elaboration Likelihood Model (ELM) and
the Motivation-Ability- Opportunity (MAO) framework, this research focuses on the
roles played by individuals’ optimistic bias as motivation and ones’ subjective health
literacy as ability to process and evaluate risk disclosures in DTCA. Specifically, this
study examined whether the degree of optimistic bias affected consumers’ risk disclosure
processing in terms of their attention to risk disclosures, their perceived importance of
risk disclosures, and their intentions to seek more risk information through alternative
sources. Further, the study examined whether the relationship between the optimistic
bias and the risk disclosure-related perceptions and intentions was moderated by
consumers’ subjective health literacy. By analyzing online survey data collected among
the U.S. adult population (N= 404), the study revealed that: (a) consumers who showed a
tendency to believe they were at lesser risk of experiencing side-effects of prescription
drugs than their peers were less likely to pay attention to risk disclosures, less likely to
perceive reading the risk disclosures as being important, and less likely to seek further
information about a prescription drug’s side-effects; (b) the relationship between
optimistic bias and intentions to seek prescription drug risk information was stronger for
consumers with high subjective health literary than for those with low subjective health
literacy. In addition to theoretical implications, practical implications and
recommendations are provided in light of a necessity to develop DTCA disclosure
messages that communicate well with consumers.
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CHAPTER I
INTRODUCTION
In the United States, direct-to-consumer advertising (DTCA) for prescription
drugs represents one of the fastest growing forms of pharmaceutical marketing (Liang &
Mackey, 2011). The expenditure on DTCA increased over fivefold from around $800
million in 1996 to $4.8 billion in 2008 (Thaul, 2009). In 2008, DTCA was one of the
biggest ad spending groups following automobiles (Nielsen Company, 2009), although
the expenditure slipped to $4.1 billion in 2010 due to the economic recession (TNS
Media Intelligence, 2011).
One of the main objectives of DTCA is to inform and to educate consumers about
prescription drugs. Since 1990s, drug manufacturers have changed their marketing
attention from physicians to consumers (IMS Health, 2003a). The increased commitment
to DTCA has led consumers to be aware of drug advertising and gain more interest in
DTC-promoted drugs and health conditions (Huh, DeLorme, & Reid, 2004). Also, drug
companies have used DTC advertising as a promotional tool to increase a drug’s sales.
There is much evidence suggesting that frequent exposure to DTC advertising is often
positively associated with consumer’s increased attention to, and desire for, the
advertised drug (Kravitz et al., 2005). Gregory J. Glover, representative of the
Pharmaceutical Research and Manufacturers of America, testified in a congressional
hearing that “Drug companies rely on DTC advertising to stimulate demand and to
increase sales for the products” (Glover testimony, 2001, p. 5).
Another important goal of DTCA for manufacturers and advertising practitioners
is to persuade consumers to talk more about drugs with their health professionals,
1

because patients need a doctor’s prescription to purchase a DTC-promoted drug (Hood,
2009). For this reason, DTC advertising is designed to drive consumers to request doctors
to prescribe drugs for them. There is evidence that this “pull” tactic to empower
consumers has been effective. For instance, research shows that doctors are more likely
to be asked to prescribe the advertised drug by consumers who are engaged with DTC
advertising than by those who are less involved with DTC advertising (Kaiser Family
Foundation, 2001b). Consumers tend to actively talk to physicians to request advertised
drugs (Kravitz et al., 2005) and do not easily give up until obtaining the requested drug
(Davis, 2000). The fact that DTCA is designed to promote a shared decision making
process between consumers and doctors is a unique characteristic of prescription drugs as
a product category (Menon, Deshpande, Perri III, & Zinkhan, 2003; Huh & Becker,
2005).
Researchers, policy makers, health professionals, and other stakeholders tend to
have strong opinions about the social value of DTCA. Proponents point out that DTC
advertising provides valuable medical information (Pfizer, 2001), motivates consumers to
actively interact with physicians (Auton, 2004; Donohue, 2006; Calfee, 2002), educates
individuals about health conditions, medications, symptoms, and treatments (Perri &
Nelson, 1987; Sheffet & Kopp, 1990), and helps reduce the overall cost of prescription
drugs (Calfee, 2002). On the other hand, opponents argue that DTCA has led consumers
to purchase unnecessary drugs and therefore inflates healthcare costs (Peyrot, Alperstein,
Doren, & Poli, 1998), forced people to ignore alternative treatment options with fewer
side-effects, and negatively affected the doctor-patient interaction (Thaul, 2009; Findlay,
2001; Lexchin & Mintzes, 2002; Wolfe, 2002). They further argue that the complex
2

medical information and unbalanced presentation between promotional messages and
warning information could confuse consumers and lead them to have misperceptions
about health issues, which could also lead to request for unnecessary drugs (Bell, Wilkes,
& Kravits, 2000; Young & Cline, 2005).
Risk Disclosures and FDA Regulations regarding ‘Fair-Balance’
Prescription drugs are distinct from other consumer products. An inappropriate
use of prescription drugs may lead consumers to experience serious, including lifethreatening consequences on one’s health. Therefore, since the late 1980s when
pharmaceutical companies started advertising prescription drugs directly to consumers,
drug ads are required by the Food and Drug Administration (FDA) to include both
promotional claims and risk information (FDA, 1999). That is, DTCA is required to be a
two-sided message. While the claims usually relate to the drug’s benefit information, the
risk disclosure section includes the medication risks and possible side-effects. The
disclosure information is often presented as a brief summary (i.e., all of the risk
information) in print ads and major statements (i.e., most important risks) with adequate
provision (i.e., giving additional sources to find full drug-related information, including
all risks) in broadcast ads (FDA, 2009).
The FDA requires that DTCA containing promotional benefits should disclose
risk information, and keep a balance between the amount and amount of benefits and
risks (Aikin, O’donoghue, Swasy, & Sullivan, 2011). According to the industry guideline
drafted by the FDA, pharmaceutical companies should follow the fair-balance principle
when advertising prescription drugs (Thaul, 2009). This means that the content and
presentation of a drug's most important risks must be reasonably similar to the content
3

and presentation of its benefits. This does not mean that equal space must be given to
risks and benefits in print ads, or equal time to risks and benefits in broadcast ads. The
amount of time or space needed to present risk information will depend on the drug's
risks and the way that both the benefits and risks are presented (FDA, 2009).
Further, the FDA emphasizes that the presentation of risks and benefits of drugs
must be “understandable, accurate, and up-to-date” (Thaul, 2009). Similarly, in 2005, the
Pharmaceutical Research and Manufacturers of America (PhRMA), a trade group that
represents the pharmaceutical industry, introduced guidelines for DTC self-regulation,
with focus on the four principles of “education, information, clarity” (Royne & Myers,
2008, p.64). The overall purpose of all these guidelines is to protect consumers from
being misled or confused by DTCA information (Gareau, 2000).
The Current Issues in Risk Disclosures
Health professionals, researchers and consumer advocacy organizations have,
however, found a number of violations of FDA guidelines for DTC advertising, and
expressed concerns about their potential impact on consumer health (e.g., Kaphingst &
DeJong, 2004; Wogalter, Dejoy, & Laughery, 1999; Royne & Myers, 2008). Researcher
found that that the benefit information presented in print DTC ads often outweighs
information about drug’s side-effects (Aitken & Holt, 2000; Kopp & Bang, 2000;
Lexchin & Mintzes, 2002) in light of prominence. In addition, although the FDA has
recommended the use of audience-friendly language in DTC ads, studies report the
textual information presented in DTC pharmaceutical materials is too technical and
difficult for the general public to understand (e.g., Kaphingst & DeJong, 2004). Sheehan
(2006) also argued that DTC advertisers tend to use controversial tactics, such as usage of
4

jargon to attenuate the accessibility of risk information, which can potentially mislead
consumers to believe that the advertised drug is less harmful than it is. In terms of DTC
TV commercials, research revealed that a popular way of promoting a drug is to depict its
benefits with various overwhelming emotional appeals and narrative stories while risk
information is relatively presented with dull and/or complex manner that is unlikely to
draw attention from consumers (Frosch, Krueger, Hornik, Cronholm, & Barg, 2007).
Thus, the current practices of DTCA have potential to mislead consumers to
receive insufficient risk information (Royne & Myers, 2008) and overestimate the
positive effects of advertised drugs, and this could inhibit their informed choice about
health problems (Kavadas, Katsanis, & LeBel, 2007). Further, it is possible that
consumers’ attitudes toward an advertised drug formed from this misperception could
pressure physicians into prescribing inappropriate treatments and generate unnecessary
discussion between consumers and doctors (Mackert, 2011).
What is more, it is important to note that there are certain consumers who are
susceptible to the limitations in the current practice of risk disclosures in DTCA. The
presence of risk disclosures in DTCA assumes that consumers are likely to have adequate
ability to understand risk information and take it into consideration in their health
decision-making (Calfee, 2002). Cox and his colleagues (Cox, Cox, & Mantel, 2010)
further mentioned that “many models of heath care decision making can be classified as
expectancy models, which imply that consumers are rational in their decision making and
use a version of weighted sum model to process and use available information” (p. 31).
However, consumers are not always rational in making their decisions (Rabin, 1998) and,
further, their motivation and ability to process information could vary (e.g., Cacioppo &
5

Petty, 1984). Accordingly, the underlying assumption embedded in risk disclosures that
consumers are rational enough to process and understand health information adequately
and they are able to make sound healthcare decisions (e.g., Calfee, 2002) has yet to be
tested.
Studied Areas
DTC advertising has impact on consumers’ decisions about drugs, the relationship
between doctors and patients and healthcare costs to some extent. Also, the constant
arguments between supporters and critics of DTC advertising, the increased DTC ad
spending and pharmaceutical manufactures’ sales growth have led researchers to answer
important questions regarding DTCA’s effects. For the most part, research in DTCA has
primarily focused on the ad category’s effects on consumer’s perceptions, attitudes and
intention. Some DTCA research has also dealt with doctor-patient relationships.
Researchers’ interest in risk disclosures in DTCA, centers around comparing the
effects of varied formats (e.g., amount, length, specificity, etc.) of risk presentation on
consumer response to such information (e.g., Morris, Mazis, & Brinberg, 1989; Tucker &
Smith, 1987; Menon et al., 2003). For example, the study by Morris (1984) compared
different formats in warning information in both print and TV ads. The study has
provided a basis for researchers to investigate manipulation effects of risk disclosures on
consumers’ recall, attitudes, and behavioral intentions (Kopp & Bang, 2000). Morris,
Brinberg, and Plimpton (1984) presented drug ads with varying amounts of benefit and
risk information, various locations where risks are disclosed, and different sources
(magazines vs. doctors’ leaflet) to participants. Results suggested that the amount and
placement of risk information and the source of such information all influenced
6

consumers’ interpretation of the drug. Similarly, risk specificity, amount of risk
information, and emphasis of risk information (Morris, Ruffner, & Klimberg, 1985) in
TV ads were manipulated to examine how consumers evaluate commercials and drugs.
The specificity and amount of risk information tended to influence consumers’ attitudes
toward the ads and their perceptions of the drug. In addition, completeness of risk
information has been studied to investigate its relationship with consumers’ perceptions
of the drug’s appeal and safety (Davis, 2000). Consumers rated drug ads with incomplete
risk information more positively than those with a more complete presentation.
Consumers’ risk awareness and knowledge could be influenced by the length and
specificity of risk information (Morris, Mazis, & Brinberg, 1989).
Understudied Areas
To date, research in DTCA disclosure effects has extensively focused on
disclosure presentation (i.e., amount, format and vividness) on consumers’ awareness and
knowledge about the risks of drugs and attitudes toward the drug ads (e.g., Davis, 2007;
Morris et al.,1989). Despite a substantial body of research, what is missing from much of
the existing discussions on DTCA disclosure is a focus on the roles of consumers’
individual characteristics in processing risk disclosures (Deshpande, 2004). Kavadas
(2003) indicated that there is a lack of studies explaining the differences in consumers’
processing of DTCA risk disclosures in light of audience characteristics. Celsi and Olson
(1988) also pointed that most studies in consumers’ information processing have focused
on how they react to product attributes and how they form their brand attitudes while
seldom dealing with consumer’s motivation, abilities and opportunities to process the
information. Hence, in a context of DTCA, it is important to examine how consumers’
7

information processing is influenced by their motivation and ability to process,
specifically, risk information in DTCA.
The Objectives of the Study
The primary purpose of the current study is to examine the role of optimistic bias
about the likelihood of experiencing side-effects of prescription drugs in influencing
consumers’ processing of, and responding to, risk disclosures in DTCA. Specifically, this
study is designed to investigate whether the degree of optimistic bias affects consumers’
risk disclosure processing in terms of their attention to risk disclosures, their perceived
importance of risk disclosures, and their intentions to seek more risk information through
alternative sources. The second objective is to examine whether the relationship between
optimistic bias and consumers’ processing and evaluation of risk disclosures in DTCA is
moderated by their subjective health literacy.
Research suggests that people tend to mistakenly believe that they have lower
chances of experiencing a negative event related to their health (Weinstein, 1980) and
this kind of cognitive tendency could result in serious health problems (Sheer & Cline,
1994). However, relatively little attention has been paid to the self-positivity and its role
in assessing risk disclosures of DTCA. Further, although several researchers (e.g., An &
Muturi, 2011) have suggested that one’s subjective health literacy is one of the important
characteristics in consumer processing of DTCA, there has been a paucity of research
discussing the moderating role of consumers’ subjective health literacy. When it comes to
understanding how consumers respond to DTCA and drug’s risks and side-effects, it is
important to examine how the ability moderates the effects of motivation in facilitating or
inhibiting consumers from accessing, understanding, and acting on the given information.
8

CHAPTER II
THEORETICAL FRAMEWORK
Optimistic Bias as Motivation to Process Risk Disclosures
Research in health beliefs reveals that one’s health-related perceptions can
influence changes in health behavior (Block & Keller, 1998). Especially, the literature on
health behavior shows that people who tend to be overconfident in their susceptibility to
health risks would not be persuaded by advertisements that deliver specific health risks or
treatment information (Roth, 2003).
In the DTCA context, one’s willingness to process risk disclosure information
could depend on the extent to which a viewer has subjective beliefs toward the drug’s
risks. In some cases, consumers could optimistically evaluate the negative effects of the
risks on them. The self positivity is referred as the optimistic bias. The optimistic bias is
defined as the illusion of invulnerability or the mistaken belief that negative outcomes or
events will less likely occur to themselves than to their peers (Weinstein, 1980).
Consumers’ varying levels of optimism about their vulnerability to drug risks could
underestimate the level of their health risks.
While one of the DTCA’s goals is to make consumers to pay attention to risk
disclosures, the extent of being optimistic or pessimistic could predict their level of
attention to risk information because the subjective belief could either activate or deactivate their motivation to process risk information (Taylor & Brown, 1988; Weinstein,
1980). The persuasion literature (Petty, Cacciopo, & Schumann, 1983) suggests that
individual motivational factors such as involvement can predict level of cognitive
elaboration leading to persuasion. The literature defines motivation as “heightening
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arousal so that inactive audiences are ready, willing, interested, or desire to process a
message” (Hallahan, 2000, p. 466). Often it has been considered goal-driven arousal
(Park & Mittal, 1985) or message processing goal (Andrews, 1988).
Some insights as to how motivation affects the processing goal can be also
retrieved from the Motivation Opportunity and Ability (MOA) framework. The MOA
framework posits that consumers’ motivation, opportunity and ability are the antecedents
to one’s level of processing advertising information (Batra & Ray, 1986; Curry &
Moutinho, 1993; Maclnnis, Moorman, & Jaworski, 1991; Poiesz & Robben,1996).
Among them, motivation denotes an inner state of willingness to acquire or dispose
information and it further serves as an activator of a goal-relevant behavior. Hence, those
consumers who have high motivation to achieve a goal (e.g., processing an ad) are likely
to devote more efforts to processing the ad, attempt to pay more attention to the
information in the ad, and are more willing to comprehend and evaluate it analytically.
Many researchers have also revealed that the level of consumer engagement with
persuasive communication is associated with their level of information processing
motivation and attention (Celsi & Olson, 1988; Petty & Cacioppo, 1986). For example, a
low processing motivation represents a low chance of paying attention to a message
(Hallahan, 2000).
From the discussion above, it is expected that consumers with a high level of
optimism toward their likelihood of having negative outcomes from advertised drugs
(e.g., side-effects) will have relatively low motivation to process information presented in
risk disclosures due to the absence of a strong goal of seeking risk-related information.
Also, those with high optimistic bias are not likely to attentively process the risk
10

information, so that they tend to avoid weighing their attentions to the risk information.
Thus, the state of low motivation can prevent consumers from being willing to engage in
a goal relevant activity (Roberts & Maccoby, 1973) and the unwillingness can lead them
to believe that the drug’s potential risks as insignificant and irrelevant. Reversely,
consumers with relative pessimism about the drug’s risks are expected to actively
respond to the risk disclosures.
Moreover, Weinstein (1989) suggests that people who perceived that they had a
lower risk of having a certain disease tend to be less willing to seek preventive or
remedial intentions. In other words, optimistic bias plays a significant role of mitigating
preventive or remedial health behaviors. Although the concept of optimistic bias has not
been extensively integrated into DTCA research, Park and his colleagues (2012) made an
initial effort in examining if more optimistically biased consumers are more likely to
avoid seeking information about the health problem related to depression. They revealed
similar results with Weinstein’s study (1989) that there was a negative relationship
between optimistic bias and intention to information-seeking. Based on the discussion
above, it is hypothesized as follows.
H1: Optimistic bias will be negatively associated with risk disclosure-related
responses. More specifically, consumers with a lower level of optimistic bias
about the likelihood of experiencing side-effects of prescription drugs are (a)
more likely to pay attention to risk disclosures, (b) more likely to perceive that the
risk disclosures are important to them, and (c) more likely to show intentions to
seek further risk information through alternative sources than those with a high
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optimistic bias about the likelihood of experiencing side-effects of prescription
drugs.
Moderating Role of Subjective Health literacy as Ability to Process Risk Disclosures
The expectation that persons’ optimistic bias about experiencing side-effects of
prescription drugs could influence their evaluations and responses to DTCA’s risk
disclosures engenders the need to examine factors that may facilitate or inhibit such a
relationship, because identifying such moderating components will shed light on better
understanding how consumers with different levels of motivation and ability process
DTCA disclosure differently. A substantial amount of research (Betmman & Park, 1980;
Batra & Ray, 1986; Davis, 1973; Petty & Cacioppo, 1986; MacInnis & Jaworski, 1989,
Zaltman & Dunca, 1977) proposes that differences in the degree to which one is able or
incapable of processing information appropriately could adjust the magnitude of
persuasion effects. Among potentially relevant variables, the present study focuses on the
moderating role of subjective health literacy, because the literature suggests that the level
of one’s ability to process information can moderate the effects of motivation to process a
message (MacInnis & Jaworski, 1989; Petty & Cacioppo, 1986).
Subjective Health Literacy.
While the amount of DTCA in the U.S is growing every year, one of the major
concerns is if DTCA’s disclosure information can be properly understood by consumers
who have relatively low ability to process health information. Surveys showed that 53%
of adults in the US had “intermediate” health literacy, 22% had “basic” and 14% had
“below basic” health literacy(Institute of Educational Sciences, 2006). In other words,
about one-third of U.S. adults fall under the category of low health literacy (National
12

Center for Education Statistics, 2003). In this regard, much evidence has pointed out that
DTCA print ads have a great amount of ‘wordy and chaotic’ style (Krisanits, 2005) and
they tend to require high ability to read and understand the content of DTCA information
(Kaphingst & Dejong, 2006). Coupled with the complex nature of medical information
presented in DTCA, consumers with low ability to process health information are at risk
because they are less able to comprehend the DTCA drug information. Further, this
inability can cause unwillingness to understand the content of risk information and it can
also lead them to make inappropriate drug-related health decisions. Young and Cline
(2005) suggested that health literacy is one of the prior conditions necessary for
consumers to comprehend the medical contents of ads. Ratzan and Parker (2006) also
emphasized that health literacy is considered to be a tool to help consumers use medical
information to make sound health decisions (Ratzan & Parker, 2006). Health literacy is
defined as “the degree to which individuals have the ability to obtain, process, and
understand basic health information and services needed to make appropriate health
decisions” (Nielsen-Bohlman, Panzer, & Kindig, 2004, p. 2). In the MOA (Motivation,
Opportunity, and Ability) framework, ability often refers to consumers’ skills or
proficiencies in interpreting a message and it is considered one of the important
determents of advertising processing (Batra & Ray, 1986; Hallahan, 2000; MacInnis &
Jaworski, 1989).
Of particular interest in this study is to examine the role of individuals’ subjective
health literacy in their processing risk disclosures in DTCA, not objective health literacy,
because one’s subjective perception is an important predictor of health behavioral
intention (An, 2007; Rock, Ireland, Resnick, & McNeely, 2005). DeJoy (1999) stressed
13

that ‘person’s subjective evaluation of the situation (risk-embedded decision) is more
important than the objective level of risk’ (p.190). Brucks (1985) also considered ones’
subjective ability to process information as a strong motivator of seeking information.
Research shows that people tend to be overconfident in evaluating their health and they
are less likely to perceive the risks to be personally relevant (i.e., Jaccard, Dodge, &
Guilamo-Ramos, 2005; Weinstein, 1980). In this study, subjective health literacy is
operationalized as how individuals perceive their ability in understanding and using
medical information.
When it comes to explaining the relationship between one’s ability to process
health information and its outcomes, research indicates that individuals’ health behaviors
are directly related to one’s confidence in their ability to execute health behavior, often
called self-efficacy (Bandura, 1986). The self-efficacy serves an important role in
predicting various health behaviors (Conner & Norman, 1998). For instance, those who
have low self-efficacy are only able to undertake undemanding tasks due to lowered
competence whereas individuals who have high self-efficacy beliefs are better able to
perform and handle more challenging behaviors (Berry & Howe, 2005). In line with
consumers’ response to DTCA, self-efficacy is also considered as playing a significant
role. Hoek and Maubach (2007) noted that self-efficacy in DTCA represents respondents’
ability to process and comprehend DTCA information, and their competence or
motivation to communicate with their doctor about the advertised drug. Research
indicated that those who have relatively low ability to processing health information are
more likely to perceive associated-risks higher than those who have high health literacy
(Ancker, & Jaufman, 2007) because of their lowered self-efficacy (Wagner, Semmler,
14

Good, & Wardle, 2009). Also, the MOA framework explains that consumers who have
high ability are more likely to interpret an ad or product-related information efficiently
and systematically because they tend to have “availability and accessibility of brandrelevant knowledge structures that provide the foundation for processing ability”
(Maclnnis, Moorman, & Jaworski, 1991, p.34). For example, experts, those who have
high ability to process product attributes, tend to better able to process more complex
information than novices whose processing focus is limited to product benefits only
(Tversky & Kahneman, 1973).
Researchers have begun recognizing the potential impact of DTCA risk
information on consumers with inadequate health literacy (e.g., DeLorme & Huh, 2009;
Kaphingst, Rudd, DeJong, & Daltroy, 2004; Wolf et al., 2005; Park & Ahn, 2012;
Markert, 2011). Especially, An and Muturi (2011) examined consumer perceptions of
DTCA and the role of subjective health literary. They interviewed 170 older adults to
examine the relationship between subjective health literacy and the educational value of
DTC ads. The study revealed that those with low subjective health literacy tended to
evaluate negatively the effectiveness of delivering key medial components in DTCA.
They argued that this tendency would be attributed to their limited ability to process
DTCA information, which prevents them from sufficiently understanding the health
information in DTCA.
Optimistic Bias and Subjective Health Literacy.
While one’s motivation is a driving force of behavior, it can’t lead the action
without ability (Cummings & Schwab, 1973; Siemsen, Roth, & Balasubramanian, 2008).
The Elaboration Likelihood Model (ELM) offers a comprehensive framework about
15

cognitive processing to understand the process of individuals’ thinking about persuasive
messages (Perloff, 2010). Basically, the ELM suggests that people’s attitudes or
judgments can be altered under various conditions of cognitive elaboration (high to low)
(Petty & Cacciopo, 1984). Specifically, related to processing of advertising, the ELM
directly posits that ability and motivation moderate the level of cognitive elaboration and
the nature of persuasion that can occur along an elaboration continuum. Thus, motivation
and ability collectively determine the amount of message elaboration (Petty, Cacioppo, &
Schumann, 1983). If consumers are both motivated to process a message and are able to
comprehend a given message, they are more likely to elaborate upon it leading to attitude
formation or attitude change (persuasion). If consumers are either not motivated or
unable to process a message, then peripheral cues in the advertising environment (e.g.,
color, layout) may influence attitude formation or persuasion. The central route (as
opposed to the peripheral route), dominated by message argument processing, will be
more effective in creating sustained persuasion (Cacioppo & Petty, 1984). This results
from greater attention to the message and scrutiny of the main arguments of the given
message (Andrew, 1988). If either motivation or ability or both is lacking, then,
processing related to the main arguments for the use of a product as advertised is
significantly decreased.
Additionally, previous consumer research has suggested that motivation and
ability are important predictors of attitudinal and behavioral changes (Davis, 1973;
Zaltman & Dunca, 1977; Petty & Cacioppo, 1986) and the components have a potential
to greatly affect persuasion and resistance. MacInnis and Jaworski (1989) also indicated
that “the impact of motivation on attention, processing capacity, operations, and their
16

associated levels of processing is moderated by processing ability and opportunity” (p.6).
Petty and Cacioppo (1996) argued that attitudes shaped or altered under high elaboration
conditions (central route) tend to reflect stronger temporal persistence and better
resistance to the counter-persuasion attacks compared with attitudes shaped or changed
under low elaboration condition reflecting a peripheral route (Haugtvedt & Petty, 1992).
Research also stressed the interaction effects of ability and motivation in processing
information. For examples, people who have relatively high motivation and high ability
tend to show the highest information processing in terms of increased consumers’ levels
of attention to and better comprehension of advertisements (Betmman & Park, 1980;
MacInnis & Jaworski, 1989; Maheswaran & Sternthal, 1990).
Based on the literature discussed, it is expected that consumers who have low
optimistic bias (high motivation to process risk disclosures) and have high subjective
health literacy (high ability to understand the content of risk disclosure) would pay more
attention to the risk disclosures, more likely to perceive that the risk information is
important to them, and more willing to search further information than the opposite
groups. Thus, the discussion leads to the following prediction:
H2: The optimistic bias for drug’s side-effects and subjective health literacy will
have an interaction on the extent of processing risk disclosures, such that the
association between the optimistic bias and dependent variables will be more
negative when consumers’ level of the subjective health literacy is high than when
the subjective health literacy is low.
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CHAPTER III
METHOD
Sample
To recruit respondents from various demographic backgrounds, a nationwide
survey was used through an online consumer survey panel. A convenience sample of 412
US consumers was initially obtained from a market research specialized firm,
Zoomerang.com. Four surveys were removed because over 10% of the questionnaire
items in the survey were not completed, resulting in a sample of 408 respondents. In this
study, multiple regression analysis was used to test the proposed hypotheses. Before
testing them, it is important to detect outliers and influential cases to meet the statistical
assumptions of multiple regression. The Casewise Diagnostics detected four cases with
Standardized Residual values over 3. Also, these four cases were judged as influential
cases with values of Cook’s distance that are greater than .0098 (4/408=4/sample size).
Thus, the four cases were pulled out of the sample cases for the final sample size of n=
404.
The sample contained diverse demographic backgrounds. The average respondent
age was 58 (SD = 10.9), ranging from 37 to 85. The sample was composed of 44.6%
women and 55.4% men. In terms of age classification, 59.4% of the sample was mature
adults (45-64) and 31.2% were older adults (65 or older) with only 9.4 % being younger
adults (37-44). In terms of ethnicity, the majority (92.3%) were whites, followed by
Asian (3.5%) and African Americans (2.2 %). All respondents reported they had used
prescription drugs in their lives. Fifty nine percent of the respondents fell into an annual
household income of $25, 000 to $99, 999 while one-fifth of the sample (20. 8%)
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reported $25,000 or less. Nineteen and three tenths percent indicated $100,000 or more
household income. In terms of education level, respondents had a college degree (27.0%)
and graduate degree (18.6%). Of respondents 29.7% completed some college, but no
degree and 7.9 % of respondents completed some graduate school, but no degree. Only
two respondents indicated having less than a high school degree.
Procedure
A recruiting email provided by Zoomerang.com was sent to the members of the
Zoomerang on-line panel. The members were asked to click the URL and they were
invited to the log-on page of the survey. Initially, IRB (Institutional Review Board) was
approved the voluntary trait of this study to fulfill participants’ protections from any
unethical approach (Appendix A). The consent was provided in the website. With their
agreement upon the study, participants participated in the survey. The entire survey took
about fifteen minutes to complete.
The survey began with an explanation of a “prescription drug” compared to overthe-counter drugs and examples of prescription medicine. Then, the instrument first
measured respondents’ personal experience with prescription drugs. It was measured by
asking respondents, “Have you ever taken a prescription drug?” Respondents were asked
to mark with “yes”, “no”, or “Don’t’ know”. The purposed of the question was to screen
out those who had never taken a prescription drug. The survey proceeded in the order of
two independent variables such as optimistic bias about the likelihood of experiencing
side-effects of prescription drugs, and subjective health literacy. Before measuring
variables related to risk disclosures, sample of DTC ads and brief summaries were given
in the survey. Among many DTC drug ads, Seroquel XR (depression medication) was
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randomly chosen. There were two ad images about benefit claims of Seroquel XR and
two pages of brief summaries about the drug’s risks and side-effects. Each image was
inserted in a small size, but respondents could zoom in by clicking the images. Every
respondent was asked to see all of the ads. Also the following instructions were provided.
“In a prescription drug magazine ad, health risks and side effects of the drug are
presented in smaller print on separate pages commonly named “brief summary”
or “important information.” These “brief summaries” frequently occupy from one
half to a full page, printed at the end of a multi-page magazine ad. We've provided
an example of a prescription drug ad so you can understand the type of
advertising we are exploring in this research study. Please be aware that the
questions in this survey are NOT about this specific advertisement. This is
ONLY an example of the basic format for various prescription drug ads and their
brief summaries. As you answer the survey questions, please think about your
own personal experiences with viewing magazine ads such as the one presented in
our example”.
Then, attention to risk disclosures, perceived importance of risk disclosures in
making drug-related decision, intentions to seek more risk information through
alternative sources and control variables including demographic variables were measured
(Appendix B).
Measures
The instrument measured two independent variables (optimistic bias about the
likelihood of experiencing side-effects of prescription drugs, and subjective health
literacy) and three dependent variables (attention to the brief summary of risk disclosures,
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the perceived importance of risk discourse in making drug-related decision, and intention
to seek further information about drug’s risks and side-effects) along with control
variables.
Optimistic bias. Respondents rated their optimistic bias about the likelihood of
experiencing side-effects of prescription drugs on a seven-point scale (1 = far less likely,
4 = about the same likelihood, 7 = far more likely) through Weinstein’s (1987) item.
Two items respectively dealing with minor and severe side-effects were developed. The
question of optimistic bias about the likelihood of experiencing minor side-effects of
prescription drugs was “Imagine that you take a prescription drug that you haven’t tried
yet, and saw advertised in a magazine. Then think of people your own age and gender.
Compared with other people your age and gender, how would you rate your chances of
experiencing minor side effects (such as drowsiness, dizziness, sleeping problems, minor
fever, trouble swallowing, or itchiness) after taking the prescription drug?”. The item of
optimistic bias about the likelihood of experiencing severe side-effects of prescription
drugs was “Imagine that you take a prescription drug that you haven’t tried yet, and saw
advertised in a magazine. Then think of people your own age and gender. Compared with
other people your age and gender, how would you rate your chances of experiencing
serious adverse reactions (such as respiratory tract infection, blurred vision, liver
abnormalities, uncontrollable muscle movement, heart diseases, or thoughts of suicide)
after taking the prescription drug?”. Correlation analysis was performed to test the
relationships between optimistic bias about the likelihood of experiencing minor and
severe side-effects of prescription drugs. The analysis found that they were positively and
significantly associated with each other (correlation coefficient = .65, P = .01). Thus,
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responses to the two items were averaged to obtain a single index representing the extent
of optimistic bias. Then, responses were reverse-coded, such that a high score stands for a
strong optimistic (M = 4.40, SD = 1.16, α = .75).
Subjective health literacy. Respondents rated their subjective health literacy on a
seven-item, 5-point scale (1= never, 3 = sometimes, 5 = always). The scales of two items
dealing with confidence were anchored by ‘not at all’ (1), ‘somewhat’ (3) and ‘extremely’
(5) (An & Muturi, 2011; Chew, Bradley, & Boyko, 2004).
1. How often are appointment slips written in a way that is easy to read and
understand?
2. How often are medical forms difficult to understand and fill out?
3. How often do you have difficulty understanding written information your
health care provider (like a doctor, nurse, or nurse practitioner) gives you?
4. How often do you have problems learning about your medical condition
because of difficulty understanding written information?
5. How often do you have someone (like a family member, friend, hospital=clinic
worker, or caregiver) help you read hospital materials?
6. How confident are you filling out medical forms by yourself?
7. How confident do you feel in following the instructions on the label of a
medication bottle?
While majority of the items are worded negatively, responses to items
representing positive ability or confidence (e.g., items 1, 6, and 7) were reverse-coded.
Then, all items were reverse scored to be consistent with the other items’ low to high
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definition, such that a higher score indicates greater subjective health literacy (M = 4.05,
SD = .64, α = .80).
Perceived attention to the risk disclosures. Respondents rated their levels of
attention to the risk disclosures in DTC advertisements on a seven-point scale (1 = not at
all likely, 7 = very likely) using the following question (Menon et al., 2003): “Imagine
that you have a health problem and are reading a magazine ad for a prescription drug that
treats the health problem, and you haven’t tried it yet. How likely would you be to read
the brief summary pages of the ad?” (M = 4.63, SD = 2.03).
The perceived importance of reading risk discourses. Respondents were asked
to rate their beliefs in how much the risk information presented in DTC advertisements is
important on a four-point scale (1 = not important at all, 2 = not too important, 3 =
somewhat important, 4 = very important) using the following item (Delorme, Huh, &
Reid, 2009): “When you see the ad, how important would it be to read the brief summary
pages?” (M = 3.04, SD = .96).
Intention to seek further information about drug’s risks and side-effects.
Respondents rated the likelihood that they would be willing to engage in certain
information-seeking behaviors regarding prescription drug’s risks and side-effects. They
rated the three statements, “I would like to learn more about the health risks and side
effects of the drug”, “When I come across other useful information about the health risks
and side effects of the drug, I would like to retain it”, and “I would like to use various
alternative sources to get more information about the drug’s health risks and side effects”
on a seven-point scale (1 = strongly disagree , 4 = neither agree nor disagree, 7 = strongly
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agree) (Huh, Delorme, & Reid, 2005). The three responses were averaged to construct a
single index reflecting information-seeking behaviors (M = 5.50, SD = 1.17, α = .83).
Control variables
Several covariates that might confound the examined effects were also measured
(Hair, Anderson, Tathan, & Black, 1998): skepticism toward DTC ad, familiarity with
DTC ad, prior exposure to DTC ad and demographic variables. Those variables were
indicated in previous studies that they have some external influences when examining
consumers’ perception and intentions to DTC ad (see An & Muturi, 2011; Huh, Delorme,
& Reid, 2004; Park & Grow, 2007; Perri & Nelson, 1987). For example, the literature
suggests that consumer’s disbelief of advertising claims, often defined as advertising
skepticism, is reported to affect advertising information processing (Obermiller &
Spangenberg, 1998). Research found that skepticism is negatively associated with
advertising responses such as attitude toward advertising, ad attentiveness, and ad
informational usefulness (Obermiller, Spangenberg, & MacLachian, 2005). Similarly,
Diehl, Mueller, and Terlutter (2007) demonstrated that consumers tend to disbelieve
claims made in prescription drug advertising. While DTCA skepticism is defined as “the
general tendency toward disbelief of advertising for prescription drugs” (Delorme et al.,
2009, p. 296), research supports that more skeptical consumers exhibited less favorable
attitude toward the source of health information (DeLorme et al., 2009) and less likely to
consider DTC advertising important (Diehl et al., 2007). Respondents rated their levels
of skepticism toward DTC ad on an eight-item, seven point scale (1 = strongly disagree,
7 = strongly agree) using the following questions (DeLorme et al., 2009): “Prescription
drug advertising is truth well told,” “Prescription drug ads generally present a true
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product picture,” “We can depend on getting the truth in most prescription drug
advertising,” “I am accurately informed by most prescription drug ads,” “Prescription
drug advertising is a reliable source of information,” “Prescription drug advertising's aim
is to inform the consumer,” “Most prescription drug advertising provides consumers with
essential information,” and “Prescription drug advertising is informative.” All items were
reverse-coded, then averaged. Thus, higher values represent higher skepticism (M = 3.20,
SD = .88, α = .95).
The literature suggests that consumers’ evaluations of the advertised product are
associated with their prior exposure to advertising (Menon & Raghubir, 2003) and their
familiarity with advertising (Hawkins & Hock, 1992). Consumers can be exposed to DTC
advertising through, not limited to, TV or Magazine or alternative information sources
such as Internet or flyers. Thus, on a six-item, seven-point scale (1 = never, 7 = very
often), respondents rated their exposure to DTC advertising from various media outlets
such as radio, newspapers, magazines, television, Internet, and other media sources
including flyers, brochures, and outdoor by the question: In the past six months, how
often have you seen, read, or heard prescription drug ads in each of the following media
types? (Huh et al., 2005). The total DTC exposure index was an average point of six
items (M = 3.44, SD = 1.42, α = .86).
Familiarity with DTC ads was measured on a six-item, seven-point scale (1 = not
at all familiar, 7 = extremely familiar) by the following question: How familiar would
you say you are with prescription drug ads in each of the following media types?
Respondents also rated their familiarity with DTC advertising from various media outlets
including radio, newspapers, magazines, television, Internet, and other media sources
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such as flyers, brochures, and outdoor The total DTC familiarity index was an average
point of six items (M = 3.11, SD = 1.47, α = .90).
Finally, demographic variables such as gender, age, education levels, and
household income were measured and controlled as covariates.
Questionnaire Pretest
To identify questionnaire problems, a pretest was conducted with a convenience
sample of thirty adults. The types of potential problems could be the understandability of
the questionnaire content, overall meaning of the questions and instructions, formatting,
measurement errors, and online survey navigation. Also, respondents were asked to
provide any thoughts, questions, or comments that they have about the survey and/or
their experience taking it. The average respondent age was 59. There were fourteen
women and sixteen men in the sample. There were no critical problems with the
questionnaire except minor grammatical mistakes. However, respondents’ friendly
instructions were added to the survey with minor grammatical editing.
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CHAPTER IV
RESULTS

Demonstrating an Optimistic Bias and Subjective Health Literacy
Respondents indicated that they tended to have their own positivistic beliefs
toward the drug’s risks relative to the risk of their peers (M = 4.40, SD = 1.16). A onesample t-test indicated that the mean 4.40 is significantly greater than the midpoint of the
optimistic bias scale (4), t (403) = 7.01, p < .001. Thus, respondents perceived their risk
of developing prescription drug’s side effects in the future to be lower than that of their
peers. On the measure of subjective health literacy, the mean rating of respondents (M =
4.05, SD = .64) was significantly greater than the midpoint of the scale (3), t (403) =
32.84, p < .001. This result indicates that respondents held relatively high subjective
health literacy.
Hypotheses testing
In order to investigate hypothesis 1 and 2, a set of hierarchical multiple regression
analyses were conducted. Prior to assessing the predictive power of optimistic bias and
subjective health literacy, a set of covariates was entered as Block 1 and Block 2.
Demographic variables such as gender, age, education and household income were first
entered in Block 1. The other three covariates, skepticism toward DTC advertising,
exposure to DTC advertisements, and familiarity with DTC advertisements, were
secondly entered in Block 2. In Block 3, two independent variables were entered:
optimistic bias about the likelihood of experiencing side-effects of prescription drugs and
subjective health literacy. Finally, in Block 4, the interaction term between optimistic
bias and subjective health literacy was entered. Prior to computing for the interaction
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term, the two independent variables were mean-centered in order to diminish the level of
multicollinearity (Aiken & West, 1991).
There are three dependent variables including a) perceived attention to risk
disclosures, b) perceived importance of reading risk disclosures, and c) intentions to seek
further drug’s risk information through alternative sources. The three dependent variables
were all significantly correlated each other (correlation between attention and intentions,
r = .53, p = .001, correlation between importance of reading risk disclosures and
intentions, r = .54, p = .001, and correlation between attention and importance of reading
risk disclosures, r = .74, p = .001,).
Basically, multiple Rs for regressions were all statistically significant across all
dependent variables. In terms of the first dependent variable, the results of the regression
showed that multiple R for regression was statistically significant, F (10, 393) = 4.51, P <
.001, R2adj = .08. Regarding the second dependent variable, perceived importance of
reading risk disclosures, results indicated that multiple R for regression was statistically
significant, F (10, 393) = 5.50, P < .001, R2adj = .10. Finally, in respect to intentions to
seek further risk information through alternative sources, results also showed that
multiple R for regression was statistically significant, F (10, 393) = 7.30, P < .001, R2adj
= .14. All significant covariates such as gender, familiarity with DTCA, and skepticism
toward DTCA were tested for potential interaction effects with significant independent
variables. No interaction effects were found.
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H1: Optimistic Bias and Risk Disclosure-related Responses
H1 predicted that optimistic bias would be negatively associated with risk
disclosure-related responses: a) perceived attention to risk disclosures, b) perceived
importance of reading risk disclosures, and c) intentions to seek further risk information
through alternative sources. Regression results on the extent of optimistic bias are
summarized in Table 1, and 2 based on the order of the dependant variables a), b), and c).
Table 1: Hierarchical Regression on Attention to Risk Disclosures in DTC ads

Statistics
Predictors

B

SED

β

Block 1
Gender

.51

.20

.13*

Age

.01

.01

.07

Education

-.06

.08

-.04

Household income

.04

.04

.06

Block 2
Skepticism toward DTCA

-.12

.11

-.05

Exposure to DTCA

.11

.10

.08

Familiarity with DTCA

.23

.10

.16*

Block 3
Subjective health literacy

.16

.16

.05

Optimistic bias

-.21

.09

-.12*

Block 4
Subjective health literacy

-.11

.12

Block ∆R2
.03*

Block ∆F
3.01*

.06**

8.43**

.01

2.94

.00

.36

-.05

× Optimistic bias
Note. *p < .05 (two-tailed). **p < .01 (two-tailed). Adjusted R2 = .08 (N = 404)
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Table 2: Hierarchical Regression on Importance of Reading Risk Disclosures in DTC ads
to Consumers

Statistics
Predictors

B

SED

β

Block 1
Gender

.31

.09

.16**

Age

.01

.00

.09

Education

.02

.04

.03

Household income

.02

.02

.04

Block 2
Skepticism toward DTCA

-.14

.05

-.13**

Exposure to DTCA

.01

.05

.02

Familiarity with DTCA

.13

.05

.19**

Block 3
Subjective health literacy

.10

.08

.07

Optimistic bias

-.09

.04

-.11*

Block 4
Subjective health literacy

-.03

.06

Block ∆R2 Block ∆F
.04**
4.22**

.07**

10.26**

.01

2.73

.00

.35

-.03

× Optimistic bias
Note. *p < .05 (two-tailed). **p < .01 (two-tailed). Adjusted R2 = .10 (N = 404)

Overall, optimistic bias contributed significantly to the prediction of all three
dependent variables. In terms of the first dependent variable, perceived attention to risk
disclosures (H1-a), the results of the regression showed that optimistic bias tended to
reduce the level of attention to risk disclosures, as a higher degree of optimistic bias
about the likelihood of experiencing drug’s risks and side-effects was associated with a
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lower level of attention to DTCA’s risk disclosures (β = -.12, p < .05). Regarding the
second dependent variable, perceived importance of reading risk disclosures (H1-b),
results indicated that optimistic bias was negatively associated with the level of
importance of reading risk disclosures (β = -.11, p < .05). Finally, in respect to intentions
to seek further risk information through alternative sources (H1-c), results also supported
the prediction that optimistic bias was also apt to reduce the level of willingness to find
more information related to risks and side-effects of prescription drugs (β = -.15, p < .01).
Moderation of the Effect of Optimistic Bias on Risk Disclosure-related Responses by
Subjective Health Literacy
H2 predicted that optimistic bias about the likelihood of experiencing side-effects
of prescription drugs and subjective health literacy would have an interaction on the
extent of processing risk disclosures, such that the association between the optimistic bias
and dependent variables would be more negative when consumers’ level of the subjective
health literacy is high than when the subjective health literacy is low.
As Table 3 indicates, optimistic bias and subjective health literacy did not have a
significant interaction effect on perceived attention to risk disclosures (H2-a) and on
perceived importance of reading risk disclosures (H2-b). However, they had a significant
interaction on intentions to seek further risk information through alternative sources (H3c).
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Table 3: Hierarchical Regression on Intention for Risk Information-Seeking

Statistics
Predictors

B

SED

β

Block 1
Gender

.44

.11

.19**

Age

.01

.01

.06

Education

-.05

.05

-.05

Household income

.03

.02

.06

Block 2
Skepticism toward DTCA

.16

.06

.09

Exposure to DTCA

.10

.06

.12

Familiarity with DTCA

.10

.06

.13

Block 3
Subjective health literacy

.24

.09

.13**

Optimistic bias

-.15

.05

-.15**

Block 4
Subjective health literacy

-.14

.07

Block ∆R2 Block ∆F
.06**
6.22**

.06**

8.20**

.03**

7.81**

.01*

4.22*

-.10*

× Optimistic bias
Note. *p < .05 (two-tailed). **p < .01 (two-tailed). Adjusted R2 = .14 (N = 404)

In terms of perceived attention to risk disclosures (H2-a), the results of the
regression showed that the association between optimistic bias and the extent of attention
to risk disclosures, was not moderated by subjective health literacy (β = -.05, p > .05).
Regarding perceived importance of reading risk disclosures (H2-b), results also indicated
a negative association, but did not attain statistical significance (β = -.03, p > .05).
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However, with respect to intentions to seek further drug’s risk information (H2-c), results
supported the interaction effect (β = -.10, p < .05). The negative association suggested
that optimistic bias’ contribution to intentions for information-searching turned more
negative as respondents’ subjective health literacy grew stronger.
To further illustrate the pattern of the moderating effect, a simple slope test was
conducted. Basically, this analysis explains as to each simple slope is statistically
different from zero (Aiken & West, 1991; Cohen & Cohen, 1983). Figure 1 portrays the
pattern of the interaction. The figure shows the main effect variable (optimistic bias)
along the X-axis, and the moderating variable (subjective health literacy), displayed with
three lines designated as high, medium, and low.
Figure 1: Moderation of the Effect of Optimistic Bias on Risk Disclosure-related
Responses by Subjective Health Literacy
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This analysis revealed that the slopes for the high level of subjective health
literacy (β = -.24, t (400) = -3.86, p < .000) and the medium level of subjective health
literacy (β = -.15, t (400) = -3.38, p < .000) were statistically significant in the association
between optimistic bias and the intentions to search more information. In contrast, the
slope for the low level of subjective health literary was not significant in the association
(β = -.09, t (400) = -3.38, p = .35). Glancing at the significant patterns of the negative
slopes (high and medium) of the regression lines indicates that the higher subjective
health literacy, the higher association between optimistic bias and the intentions to seek
prescription drug risk information. Turning to the respondents with lower subjective
health literacy, the association between optimistic bias and the intentions to seek
prescription drug risk information decreased and became non-significant. It means that
there is no effect of optimistic bias on the intentions especially for the respondents with
low health literary.
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CHAPTER V
DISCUSSION OF FINDINGS

Although the effects of persuasive communication can be achieved from various
sources of influence, the present study focused on the role of optimistic bias about the
likelihood of experiencing side-effects of prescription drugs and subjective health literacy
in the consumer processing of risk disclosures in DTCA. Specifically, this study
examined how consumers’ optimistic bias influenced their attention to risk disclosures,
their perceived importance of reading risk disclosures, and their intention to seek
information about the risks and side-effects of prescription drugs. Further, the current
study examined whether the relationship between the optimistic bias and the risk
disclosure related perceptions and intentions was moderated by consumers’ subjective
health literacy. Findings of the study have theoretical and practical implications in light
of message strategies for risk disclosures in DTCA.
Optimistic Bias
As predicted, the study revealed that consumers who showed a tendency to
believe they were at lesser risk of experiencing side-effects of prescription drugs than
their peers were less likely to pay attention to DTCA’s risk disclosures, less likely to
perceive reading risk disclosures as being important, and less likely to seek further
information about drugs’ side-effects. In other words, willingness to process risk
disclosures depended on the extent to which a viewer has his/her own positivistic or
pessimistic beliefs toward the drug’s risks relative to the risk of their peers. This finding
is consistent with the literature in health beliefs suggesting that one’s health-related
perceptions can influence chances of health behavior (Block & Keller, 1998). As the
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optimistic bias is considered as a strong antecedent of intentions for health behavior
(Park, Ju, & Kim, forthcoming), the high optimism and the resulting low-motivation to
process health information may inhibit consumers from processing and understanding
important health information sufficiently. It is important to note that consumers with high
optimistic bias for drug-risks could believe that they were invulnerable to drugs’ sideeffects and would pay minimal attention to drug risk information in DTCA, which could
be essential to informed decision making on health issues.
Further, the results give a clue that people who tend to be overconfident in their
susceptibility to health risks would not be affected by advertisements which convey
specific health risks or provide treatment information (Roth, 2003). In other words, what
determines the efficacy of persuasive manipulations is consumers’ motivation to process
health information. From this perspective, it will be critical for DTC practitioners to
come up with risk disclosure message strategies which reduce target audience’s illusion
of invulnerability—that they have a lower likelihood of experiencing health risks and
side-effects of prescription drugs than their peers.
The Moderating Role of Subjective Health Literacy
The current study also revealed that the relationship between the optimistic bias
and the intentions to seek prescription drug risk information was stronger for consumers
with high subjective health literary than for those with low health literacy. This pattern
was not statistically significant for perceived attention and perceived importance
variables. In fact, an additional regression analysis indicated that the subjective health
literacy did not contribute significantly to perceived attention to risk disclosures (β = .05,
p > .05), and perceived importance of reading disclosures (β = .07, p > .05), although
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each regression analysis showed that subjective health literacy was positively associated
with the level of attention and the degree of importance of reading risk disclosures.
One possible interpretation of this insignificant effect is that the main interest of
the current study was confined to a sample with some degree of prescription drug
experience. However, it is possible that the degree of prescription drug use could affect
consumers’ DTC ad information processing. Research found that consumers’ prior
experience with products is positively associated with their level of attention to
advertising and advertising information processing (e.g., Brucks, 1985; Menon et al.,
2003). In fact, about half of Americans are currently using prescription drugs and people
that reported taking more than one prescription medication in the past month has
gradually increased from 43.5 % to 48.3% through 1999 to 2008 (National Health and
Nutrition Examination Survey, 2010). In other words, it is likely that those consumers
with different level of prescription drug experience (e.g., heavy users vs. light users) will
perceive risk information differently. In this regard, it is necessary to account for varying
levels of prescription drug usage into consumers’ processing of DTCA risk disclosures.
Thus, as a future study, it is important to explore how consumers’ prescription drug usage
affects the risk-disclosure information processing mechanism.
Another possible explanation is related to the items of the subjective health
literacy used in this study. Because the measure deals with one’s general ability to
process health information, the items have been too broad to the specific context of
consumer processing of risk information. Accordingly, future research should consider
modifying the items of subjective health literacy in light of DTCA disclosure.
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Further, the current study revealed an interaction effect that the higher subjective
health literacy, the stronger relationship between the optimistic bias and the intentions to
seek prescription drug risk information. When consumers’ subjective health literacy was
high their low optimistic bias (high motivation to process information presented in risk
disclosures) linked to an increased desire for information search related to drug’s risks
and side-effects. The finding is consistent with the prediction made by MAO framework
and ELM that the consumers’ motivation and ability have a positive association with
their levels of information processing (MacInnis & Jaworski, 1989; Petty & Cacioppo,
1986). However, the interaction effect was contingent upon the degree of the subjective
health literacy. The interaction effect was not seen for those who have relatively low
subjective health literacy. For those who had low subjective health literacy the optimism
toward drug’s side-effects did not significantly enhance their intention to seek further
information about drug’s risks and side-effects. This pattern suggests that one’s
subjective ability to process health information could inhibit them from seeking to
understand the given drug disclosures.
Theoretical and Practical Implications
The current study has theoretical implications for DTCA and DTCA disclosure
research. Because DTCA is designed to promote a shared decision making process
between consumers and doctors (Huh & Becker, 2005), which is a unique characteristic
of the advertising category, it is critical to consider consumers’ motivation to inquire
about health risks and side-effect of advertised drugs via alternative sources and their
perceived ability to understand the content of information presented in the risk
disclosures. However, the literature has largely neglected such important audience factors
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as motivation and ability to process risk disclosures in DTCA (Kavada, 2003; Deshpande,
2004) while a great amount of DTCA studies in risk disclosures tends to focus on
examining the effects of various formats (amount, length, specificity) of risk disclosures
on audience responses to such information (e.g., Morris et al., 1989). While the social
psychology literature has considered the role of the optimistic bias in a variety of areas
such as accidents (McKenna, 1993), crime, (Perloff & Fetzer, 1986) and depression
(Kuiper, MacDonald, & Derry, 1983), to the best of the author’s knowledge, the current
research is the first empirical study to incorporate the concept of optimistic bias in the
context of DTCA disclosure. Thus, this study has theoretical implications for DTCA and
DTCA disclosure by inviting a variety of research avenues in terms of optimistic bias and
its application to DTCA. Additionally, the current study revealed the role of subjective
health literacy in moderating the effects of optimistic bias on consumers’ information
seeking intent in the context of DTCA. Thus, this research not only adds an important
aspect to the optimistic bias to the literature, but also it sheds light on better
understanding how consumers with varying levels of motivation and ability process
DTCA disclosure differently.
The current study has also practical implications for DTCA practitioners, FDA
regulators and policy makers. Specifically, this study can contribute to the development
of effective and creative disclosure message strategies tailored to consumers with
different levels of optimistic bias about drug-related side-effects and various degrees of
subjective health literacy.
The present study revealed that a low processing motivation and low processing
ability reflected a low chance of gaining attention to a disclosure message. Further this
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study found the moderating role of subjective health literacy in reducing the effects of
optimistic bias for drug’s side-effects on the intention to seek further information about
drug’s risks and side-effects. These findings imply that consumer’s willingness to engage
in information seeking behaviors regarding drug’s side-effects is not only a function of
their positivistic tendency toward drug’s risks but also a function of their subjective
health literacy. There are great concerns that consumers with low health literacy are less
likely to obtain, process, and act on information in the current practice of DTC
prescribing drug ads (Kaphingst, Rudd, Dejong, & Daltroy, 2005) due to the conventional
style of DTC ads where the proportion of drug benefit claims often outweighs the sideeffect information, emotional appeals dominantly deliver the merits of drugs, and risk is
portrayed through technical terms (Roth, 2003). The study’s finding lends support to such
concerns and further suggests that it is important for DTCA marketers to acknowledge
that these situations might lead consumers with low subjective health literacy to become
reluctant to exert their high motivation to process risk-disclosure information. Thus, it is
important for DTCA practitioners to develop risk-disclosure messages tailored to those
consumers with relatively low subjective health literacy and high optimistic bias toward
prescription drugs’ side-effects.
Then, how can DTCA practitioners create a risk disclosure message that reduces
the optimism toward drugs’ risks and alleviates the problems with consumers with low
health literacy? Also, is there any new approach of breaking down the old and
conventional style of DTC ads?
One of the possible ways is to design a corrective risk disclosure message which
directly challenges the mistaken belief that drug-related risks could be more prevalent to
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others than me. Another way is to place an instruction in front of the health benefit
claims of the DTC ads. As a form of forewarning (Apsler & Sears, 1968; Petty &
Cacioppo, 1986; McCroskey, 1968; Papageorgis, 1968), the instruction could include a
short introductory message that acknowledges consumers’ general optimism toward
prescription drugs, such as the following: “you may think that you will never experience
prescription drug side-effects. However, everyone’s body is different, and not all drugs
provide ideal benefits for everyone”. Prior research in cognition and perception suggests
that a salient factor in a message draws an attentional focus (Taylor & Thompson, 1982)
and the maintained activation causes information processing motivation (Hallahan,
2000). Thus, the type of instruction might serve to draw attention from message
recipients, especially those who have relatively high optimistic bias about the likelihood
of experiencing the side-effects of advertised drugs or those who have low health literacy.
Also even after being exposed to the drug benefit claims, it continues in motivating them
to process drug-related risk information which is typically presented at the end of the
DTC ads. In contrast, for those with a pessimistic bias about experiencing side-effects of
prescription drugs, an introductory message could be modified to state that “Providing
you with risk information in this ad does not necessarily mean that you would develop the
side-effects after you take the drug. Like everything, a drug could have two sides: merits
and risks.”
DTCA practitioners can also make variations of the suggested instruction content
and associated disclosure presentation formats. However, on a practical level it would be
challenging for DTCA advertisers to know if the target audience has an optimistic bias or
not, or adequate health literacy or not. In this case, the question is how would advertisers
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know which introductory message to use, when would it be idealistic to send the
messages and via what types of media outlets. One possible way is to survey the
distribution of US citizens’ degree of optimistic bias toward a prescription drug’s risks
and side-effects and their level of health literacy toward risk disclosures. Then, for
instance, the recommended message could be distributed to the regions or states where a
relatively higher density of those individual factors exists.
In terms of individualized warning disclosure, new technology such as the QR
(Quick Response) code could also be a factor. For example, magazine readers could scan
the QR code on a page of a DTC ad in a magazine via their smart phones. Then, the smart
phone could ask if the reader is generally optimistic or pessimistic toward drug’s sideeffects. Or the code could have the potential to allow readers to pull information related
to the side-effects of the advertised prescription drug in easy to read language. Such
methods might provide strategic directions regarding which type of disclosure message
works most effectively to activate the audience’s attention to risk disclosures in DTCA,
to adjust individuals’ illusion about their own risks relative to the risk of others, and to
break down the conventional style of the current DTC ads. Additionally, it is worth
noting that much remains to be empirically tested about how these introductory messages
could be applied in various media outlets and about how consumers will react to these
messages.
Also, one might call to question the practical implementation of the suggested
message approaches in the context of promotional DTCA because some DTCA
advertisers may be reluctant to communicate with consumers specifically about
additional explanations of drugs’ risks more than the amount of risk information required
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by FDA. Nevertheless, there are alternative forms of DTC ads: 1) Reminder ads that only
include the name of drug’s brand without health problems, risk disclosures or benefits. 2)
Help seeking ads that, which are exempt from the name of drug’s brand and drug’s risks,
include only health issues or the disease. If necessary, on the one hand, the
pharmaceutical industry and practitioners could consider running the proposed messages
(they could be modified in different ways) via those alternatives. On the other hand,
because the FDA does not require the industry to carry risk information in those two
types of ads, they could develop new type of educational DTC ads which are primarily
intended to reduce consumer’s misperceptions (optimism/pessimism) or to how to find
more tailored information via alternative sources. By doing so, DTCA advertisers could
gain long-term credibility as well as promote the public’s long term health.
The focus of the current study was geared toward consumers’ individual factors
and their influences on consumer processing of, and response to, risk disclosures in
DTCA. While Ryone and Myers (2008) stressed that the attention of DTCA research
should be given to exploring the nature of DTCA disclosure from consumers’
perspectives and to providing consumer-oriented policies, research in DTCA disclosure
has largely focused on the amount or format of the risk disclosures and its impacts on
consumers without considering consumers’ unique individual characteristics. In addition,
based on the emerging research trend in DTCA disclosure format studies, it is generally
acknowledged that sticking to the rule of FDA guidelines (e.g., fair balance between
promotional message and side-effects information; plain language, etc.) are sensible
when it is seen from the lens of FDA’s consumer safety policy; however, we should bear
in mind that it is more important for policy-makers, FDA, DTC advertising makers, and
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drug manufacturers to understand the concept of “fair-balance” from the perspective of
consumer’s main interest and their true needs. Specially, it is important to note that
providing a full range of information about a drug’s benefits and risks is not always
advantageous, especially for those who have low subjective health literacy.
For example, with respect to easy-to-read risk disclosures, some researchers
pointed that “the lack of explicitness or usage of vagueness of terms in most consumer
product warnings is that manufacturers avoid them because of the belief that explicit
warnings will deter people from purchasing their product, compared to a competitors’
product with a less explicit warning” (Wogalter, Dejoy, & Laughery, 1999, p.154). On
the other hand, it is indispensable to acknowledge that language in risk disclosures is
impacted by legal liability issues and the wording might be such as to avoid liability
rather than any particular intent of advertising creatives to deceive or discount the
information. In either case (risk disclosures with more audience friendly language vs. risk
disclosures with technical terms), one more issue to be considered is that those who with
low health literacy may be lost in the wave of the lengthy risk information (e.g., if the
benefit claims and side-effects information in a DTC print ad are overly long), not
because of indecipherable terms, but because of information overload. Researchers
pointed out that the traditional practices of print DTC ads, which contain excessively long
and complex side-effects, are not always favored by consumers (Aikin, O’Donoghue,
Swasy, & Sullivan, 2011). Recent studies (Duke, Friedlin & Ryan, 2011; Liang &
Mackey, 2009) also indicated that the presence of over-warning can induce information
overloading not only to consumers but also even physicians. Thus, the instructional
message for consumers with low health literacy could add the following statement,
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“Please try to read the risk information provided at the end. If you can’t fully understand
it, please remember to ask your doctor about the drug’s potential risk.” Hence, the topic
of this investigation is pertinent to policymakers and FDA regulators in that they could
reevaluate the current practice of DTCA disclosure from the consumers’ perspectives.
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CHAPTER VI
LIMITATIONS AND SUGGESTSION FOR FUTURE RESEARCH
Like other research, this study has a number of conceptual limitations. First of all,
the current study mainly focused on the role of optimistic bias only about the likelihood
of experiencing risks and side-effects of prescription drugs. However, one may argue that
this study did not capture the full picture of optimistic biases toward DTC advertising due
to the absence of optimistic bias toward certain diseases such as diabetes, or depression.
A future study should deal with both dimensions in estimating optimistic bias toward a
certain disease and the self- positivity about the prescription drug’s risks and side-effects
for the disease simultaneously.
In addition, this study did not examine the underlying or intertwined factors of the
optimistic bias. The social psychology literature stresses that the optimistic bias is not a
sole construct. Rather, many other layers could be involved with it such as emotion or
mood (Helweg-Larsen & Shepperd, 2001). Also, it could generate different effects
depending on the respondents’ personal health condition, health sensitivity, or the degree
of reliance on their physicians. For example, research found that the insertion of photos
of a similar person in an anti-drunk driving ad tended to reduce respondents’ optimistic
bias toward a depressing outcome (Riesenberg, 2005). Thus, a future study should find
out various factors which influence the likelihood and magnitude of the optimistic bias,
especially related to DTC ads processing. Moreover, while the current study did not
cover what drives the optimism or how it is composed in various situations, a qualitative
in-depth interview could handle with those issues.
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A future study could also touch upon the relationship between consumers with
high optimistic bias experiencing side-effects of DTC drugs and consumers who have
been suffering from substance abuse. Research indicates that millions of U.S. citizens
have been involved in drug abuse (World Health Organization, 2009). Further, a report
by Substance Abuse and Mental health Services Administration (2005) showed that about
52 million people (about 20 percent of people in the U.S.), especially common in younger
age groups, have experienced prescription drug abuse, which is the use of a prescription
medication for reasons other than intended when prescribed. Teenagers often share
prescription drugs for a various purposes, such as losing weight, getting high or enhanced
studying, which has a potential to lead serious outcomes including addition, or even
worse, death by overdose. It is important to note that “risk behavior is linked to
perceptions of relative risk perception; people will engage in risky behavior if they
perceive they are at relative lesser risk than other people” (Helweg-Larsen, & Shepperd,
2001, p.91). Those who have relative high optimistic bias toward drugs in general may be
more likely to consider taking illicit drugs, which can result in serious outcomes. Thus, a
future study may empirically test if the association is valid and further investigate
possible ways to solve this issue.
This study attempted to understand persuasion processes guided by the MOAframework and the ELM, mainly focusing on the moderated effects on motivation and
ability. However, one of the supplementary determinants in information processing
guided by the MOA model is opportunity (Andrews, 1988; Batra & Ray, 1986; Curry &
Moutinho, 1993; MacInnis & Jaworski, 1989; MacInnis et al., 1991). While the ELM
tends to subsume the notion of opportunity under the ability component, it should be
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noted that the MOA-framework makes explicit distinction between motivation,
opportunity and ability (Poiesz & Robben, 1996). Also, the utilization of two components
(motivation/ability) is relatively favored in the studies of advertising and persuasion
literature without ‘priori theoretical or meta-theoretical reasons’ (Poiesz & Robben, 1996,
p. 231). Although it can be assumed that opportunity is almost a media planning variable
(getting the message out there to the right people and giving them enough time to process
it centrally), it is important to examine the role of opportunity in context of message
availability, message repetition, and message variation. Schumann and his colleagues
(Schumann, Kotowski, Ahn, & Haugtvedt, 2012) stressed the necessity of empirically
testing how message reoccurring experiences (opportunity) can serve to understanding
consumers’ information processing. Derived from the MOA-framework (Motivation,
Opportunity, and Ability), future studies should test the role of moderators (motivation
and ability) under the availability of sufficient ‘opportunity’ to comprehensively
understand the nature of the persuasion process, preferably in an experimental setting.
DTC ads for prescription drugs are required to include risk disclosure information
when speaking of a drug’s potential benefits, thus forming a mandatory two-sided
message. Admittedly, DTC ads tend to maintain complex medical information
specifically in the risk disclosures (Young & Cline, 2005). Information processing theory
suggests that individuals who are naturally willing to engage in effortful cognitive
activity are more likely to attend to and scrutinize complex messages (Cacioppo & Petty,
1982). Need for cognition (NFC), referred as the extent to which individuals have inner
motivation for cognitively challenging tasks, can affect individuals’ DTC advertising
message processing. Considering the complex nature of DTC messages and their formats,
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consumers could have different responses to the DTC ad benefit messages and risk
disclosures depending on the consumers’ level of need for cognition. Thus, future
research should take into account this important motivational variable in light of various
dimensions of consumer cognitive activity.
According to the National Health and Nutrition Examination Survey (Centers for
Disease Control and Prevention, 2010), not only are almost half of Americans
prescription drug users, but also there is a considerable increase in the percentage of
Americans using prescription drugs in the U.S over the last 10 years. For instance, those
who took at least one or more prescription medication in the past month have been
steadily increasing from 43.5 % in 1999 to 48.3% in 2008. Also, the survey reported that
the 76 percent of older Americans (over 60 years old) are likely to take two or more
prescription drugs while 37 percent of the group tends to take five or more prescription
drug. In this case, it is not difficult to surmise that there are differences between heavy
and light prescription drug users in terms of their level of attention to risk disclosures in
DTCA and intention to search for further information related to a drug’s side-effects.
Research indicated that consumers who have used prescription drugs on a regular base
were less likely to pay attention to risk disclosures in magazines (Menon et al., 2003).
Furthermore, Menon and his colleagues suggested that consumers’ increased use of
prescription drugs might have led them to believe that their knowledge about their
prescription drug goes beyond what they can get from the risk disclosures in DTCA. The
literature in consumer research also suggested that consumer product experience is
associated with advertising information processing (e.g., Brucks, 1985; Park & Lessig,
1981). Thus, in addition to the level of optimistic bias and subjective health literacy, there
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still could be variances across one’s experience with prescription drugs which could
affect the attention to risk disclosures or information seeking behavior. Future researchers
should consider testing the role of one’s usages of prescription drugs in processing
DTCA risk disclosures.
Methodologically, this study has some limitations. First of all, this study
analyzed survey data and provided correlational interpretations. These alluded causal
relationships, however, may limit the explanation of causality (Meehl & Waller, 2002).
Future research should be conducted in an experimental setting to be able to account for
sufficient causal interpretations. For instance, to examine if the introductory risk
disclosure could activate respondents’ attention to prescription drug’s side-effects and
motivating them to process the risk information, the suggested message treatment “you
may think that you will never experience prescription drug side-effects. However,
everyone’s body is different, and not all drugs provide ideal benefits for everyone” could
be presented to those in an experimental group. The message treatment should not be
given to those in a control group while all other conditions are identical. Throughout this
type of research method, a relatively strong interpretation for causality could be achieved.
Although the high response rate of 22% (total delivery: 1800) seems promising on
the quality and outlets of the instruments, another potential limitation is that online
sample cannot represent the attributes of general population. In this study, the sample was
mainly composed of older people with an online questionnaire. It might be true that the
same is somewhat biased by better educated, more affluent, and more forward thinking
individuals. Thus, the research findings should be replicated with more representative
samples.
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In this study, the items of the subjective health literacy were borrowed from the
existing literature (An & Muturi, 2011). However, it is possible that the measures did not
precisely capture the nature of subjective healthy ability to understand and process risk
disclosure information in DTCA. For example, the items such as filling out medial forms
or understanding to take two pills ad day by doctor’s instructions may be different from
attention to complex side-effect information of prescription drugs. Hence, the direct
application of the subjective health literacy to the study of DTCA and DTCA disclosure
should be made with caution. Future researchers might consider developing subjective
health literacy items, especially geared to the DTC advertising condition. For example,
the following types of scale modification could be made: 1. How often are the directions
and instructions on the brief summary pages difficult to understand? 2. How often are
the specific health risks and side-effects information on the brief summary pages difficult
to understand? 3. How often are the numbers, probability and statistics presented in the
brief summary pages difficult to understand? 4. When reading the brief summary pages,
how helpful do you find tables and graphs that are part of the drug’s information? 5.
When reading the brief summary pages, how helpful do you find words (“it rarely
happens”) that are part of the drug’s information? 6. When reading the brief summary
pages, how helpful do you find numbers (“there’s a 1% chance”) that are part of the
drug’s information? 7. How often do you have someone (like your health care provider)
help you read the health risks and side effects information on brief summary pages?
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Appendix A- Consent Form

* Prescription drugs and prescription drug advertisements:
Thank you for your willingness to participate in this study. Your participation will help
researchers better understand the thoughts, feelings, and opinions Americans have about
a variety of health issues and health information. The information you provide will be
confidential and anonymous. The researcher has no means or intention to reveal your
personal identity or connect your responses with your personal identity at any stage of the
project, including data collection, analysis, and reporting of the survey results. In
addition, Zoomerang does not represent the principal investigator in any way, and will
not misrepresent your responses to serve the researcher’s agenda. There are no
anticipated risks for study participants. However, if you do not wish to answer a question,
you may skip it. If you wish to quit the project at any time, simply close the survey web
site. If you have questions about the study or the procedures, you may contact the
researcher, Anthony Ahn, at 103 Communications Building, Knoxville, TN 37996, by
phone at 865-974-8007, or by e-mail at hahn5@utk.edu. If you have any questions about
your rights as a participant, contact Research Compliance Services at 865-974-3466.
You must be 18 or older to participate. Participation in this survey is completely
voluntary, but if you participate, you will earn ZoomPoints. It takes approximately 18-20
minutes to complete the survey. By completing the survey, you provide your consent to
participate. If you stop midway through the survey and close the survey web site, the
partially submitted data will remain in the principal investigator’s survey account. If you
wish to, you can re-enter the survey and finish it as long as the survey project is still
available. Thank you for the invaluable help you are providing by participating in this
research study.

1. Are you 18 years of age or older?
Yes
No
2. I have read the above informed consent, and provide my consent to participate in
this study.
Yes
No
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Appendix B- Questionnaire
Unlike over-the-counter drugs such as aspirin or vitamins, you need a doctor’s
prescription to buy a prescription drug. Examples of prescription medicine include
drugs used to treat diabetes, depression, arthritis, heart disease, osteoporosis,
hypertensions, allergies, cholesterol, asthma, and birth control, among others. To
promote prescription drugs, pharmaceutical companies often place their ads in
media outlets used by consumers like you, such as newspapers, magazines,
television, and Internet. The primary focus of this survey is on your thoughts and
feelings about consumer-directed prescription drug advertising. The survey is not
designed to judge your opinions about this issue, so there are no right or wrong
answers to the following questions.
3. Have you ever taken a prescription drug?
Yes
No
Don't know
************************************************************************
Imagine that you take a prescription drug that you haven’t tried yet, and saw advertised in
a magazine.
4. Then think of people your own age and gender. Compared with other people your
age and gender, how would you rate your chances of experiencing minor side effects
(such as drowsiness, dizziness, sleeping problems, minor fever, trouble swallowing,
or itchiness) after taking the prescription drug?
about the
far less
slightly less
same
slightly
far more
likely
less likely
likely
likelihood more likely more likely
likely
1

2

3

4

5

6

7

5. Compared with other people your age and gender, how would you rate your
chances of experiencing serious adverse reactions (such as respiratory tract
infection, blurred vision, liver abnormalities, uncontrollable muscle movement,
heart diseases, or thoughts of suicide) after taking the prescription drug?
about the
far less
slightly less
same
slightly
far more
likely
less likely
likely
likelihood more likely more likely
likely
1

2

3

4
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5

6

7

Here, I would like to ask you how much you understand medical information and
instructions you might see around the hospital. Check the scale that best represents your
response to each statement.
6. How often are appointment slips written in a way that is easy to read and
understand?
never
occasionally sometimes
often
always
1

4

5

7. How often are medical forms difficult to understand and fill out?
never
occasionally sometimes
often

always

1

2

3

2

3

4

5

8. How often do you have difficulty understanding written information your
healthcare provider (like a doctor, nurse, or nurse practitioner) gives you?
never
occasionally sometimes
often
always
1

2

3

4

5

9. How often do you have problems learning about your medical condition because
of difficulty understanding written information?
never
occasionally sometimes
often
always
1

2

3

4

5

10. How often do you have someone (like a family member, friend, hospital-clinic
worker, or caregiver) help you read hospital materials?
never
occasionally sometimes
often
always
1

2

3

4

11. How confident are you filling out medical forms by yourself?
not at all
a little bit
somewhat
quite a bit
1

2

3

4

5

extremely
5

12. How confident do you feel in following the instructions on the label of a
medication bottle?
not at all
a little bit
somewhat
quite a bit
extremely
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1

2

3

4

5

In a prescription drug magazine ad, health risks and side effects of the drug are presented
in smaller print on separate pages commonly named “brief summary” or “important
information.” These “brief summaries” frequently occupy from one half to a full page,
printed at the end of a multi-page magazine ad.
We've provided an example of a prescription drug ad so you can understand the type of
advertising we are exploring in this research study. Please be aware that the questions in
this survey are NOT about this specific advertisement. This is ONLY an example of the
basic format for various prescription drug ads and their brief summaries.
As you answer the survey questions, please think about your own personal
experiences with viewing magazine ads such as the one presented in our example.
13. Please take a moment to view the following images. You can zoom in by clicking
the images.
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Imagine that you have a health problem and are reading a magazine ad for a prescription
drug that treats the health problem, and you haven’t tried it yet.
************************************************************************
15. When you see the brief summary pages, how much attention do you think you
would pay to the health risks and side effects information on the pages?
very much
no attention
attention
1

2

3

4

5

6

7

************************************************************************
16. When you see the ad, how important would it be to read the brief summary
pages?
not
not too
somewhat
very
important at all
important
important
important
1

2

3

4

************************************************************************
Imagine that you have a health problem and have just read the brief summary pages of a
prescription drug ad that treats the condition, and you haven’t tried it yet.
The following statements represent actions you may take after seeing the ad. How much
do you agree with each statement?
17. I would like to learn more about the health risks and side effects of the drug.
neither
agree
strongly
somewhat nor somewhat
strongly
disagree disagree disagree disagree agree
agree
agree
1

2

3

4

5

6

7

18. When I come across other useful information about the health risks and side
effects of the drug, I would like to retain it.
neither
agree
strongly
somewhat nor somewhat
strongly
disagree disagree disagree disagree agree
agree
agree
1

2

3
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4

5

6

7

19. I would like to use various alternative sources to get more information about the
drug’s health risks and side effects.
neither
agree
strongly
somewhat nor somewhat
strongly
disagree disagree disagree disagree agree
agree
agree
1

2

3

4

5

6

7

************************************************************************
20. In the past six months, how often have you seen, read, or heard prescription
drug ads in each of the following media types?
never

very
often

occasionally

Prescription
drug ads in radio

1

2

3

4

5

6

7

Prescription
drug ads in
newspapers

1

2

3

4

5

6

7

Prescription
drug ads in
magazines

1

2

3

4

5

6

7

Prescription
drug ads in
television

1

2

3

4

5

6

7

Prescription
drug ads in the
Internet

1

2

3

4

5

6

7

Prescription
drug ads in other
media (flyers,
brochures,
outdoor, etc.)

1

2

3

4

5

6

7

************************************************************************
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21. How familiar would you say you are with prescription drug ads in each of the
following media types?
not at all
moderately
very
familiar
familiar
familiar
Prescription drug
ads in radio

1

2

3

4

5

6

7

Prescription drug
ads in
newspapers

1

2

3

4

5

6

7

Prescription drug
ads in magazines

1

2

3

4

5

6

7

Prescription drug
ads in television

1

2

3

4

5

6

7

Prescription drug
ads in the
Internet

1

2

3

4

5

6

7

Prescription drug
ads in other
media (flyers,
brochures,
outdoor, etc.)

1

2

3

4

5

6

7

************************************************************************
22. For each statement, please check a box to indicate your agreement.
strongly
neither agree
strongly
disagree
disagree
nor disagree
agree
agree
Prescription drug
advertising is
truth well told.

1

2

3

4

5

Prescription drug
ads generally
present a true
product picture.

1

2

3

4

5

We can depend
on getting the
truth in most
prescription drug

1

2

3

4

5
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advertising.
I am accurately
informed by
most
prescription drug
ads.

1

2

3

4

5

Prescription drug
advertising is a
reliable source of
information.

1

2

3

4

5

Prescription drug
advertising's aim
is to inform the
consumer.

1

2

3

4

5

Most
prescription drug
advertising
provides
consumers with
essential
information.

1

2

3

4

5

Prescription drug
advertising is
informative.

1

2

3

4

5

************************************************************************
23. Your gender is
Male
Female
24. Your age is _____________________
25. Do you consider yourself...?
White
Black
African American
Asian or Pacific Islander
Native American or Alaskan native
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Mixed racial background
Not sure
26. What is the highest level of education you have completed?
Less than high school
Completed some high school
High school graduate or equivalent
Completed some college, but no degree
College graduate (e.g., B.A., A.B., B.S.)
Completed some graduate school, but no
degree
Completed graduate school
Not sure
Decline to answer
27. Have you ever had a health-related job?
Yes, currently
Yes, in the past
No
28. Think back over the past few months; how many times have you taken
prescription drugs?
None
Once per week
Twice per week
3 to 5 times per week
6 to 9 times per week
10 or more times per week
29. What is your annual household income?
Less than $14,999
$15,000 to $24,999
$25,000 to $34,999
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$35,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
$100,000 to $124,999
$125,000 to $149,999
$150,000 to $199,999
$200,000 to $249,999
$250,000 or more
Not sure
Decline to answer
30. Is English your first language?
Yes
No
Not sure
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